Co-Diagnostics, Inc. - 8-K Filing
Co-Diagnostics reports Q3 2026 revenue of $0.3 million and a net loss of $6.3 million, noting two regulatory submissions under review in the U.S. and India. (Items: 2.02 Results of Operations and Financial Condition, 7.01 Regulation FD, 9.01 Financial Statements and Exhibits)
Tickers: $CODX
Read the full article at SEC EDGAR
Part of the story Noble Corp plc - 8-K Filing (63 articles)